We are kicking off March Monday Meetings with Jimmy Rosen, life sciences partner at Intersouth Partners in Durham, North Carolina. Jimmy joined Intersouth in 2005 after spending 15 years in clinical, research and financial positions in the health care and biotechnology sectors.
Jimmy worked on a Robert Wood Johnson Foundation sponsored program at the UNC Lineberger Comprehensive Cancer Center. He was also an equity research analyst at Brean Murray & Co. for three years, covering biopharmaceuticals, genomics, generics, drug delivery and medical device companies. He has worked in clinical research roles at Duke University Medical Center’s Comprehensive Cancer Center and completed projects for the National Cancer Institute. At the beginning of his career in health care, Jimmy spent five years in Emergency Medical Services as a mountain search rescue and ambulance medic.
His current portfolio includes ABT Molecular Imaging, Applied Genetic Technologies Corporation, Aresenal Medical, Cempra Pharmaceuticals, and Viamet Pharmaceuticals. He currently serves on the Acceleration Advisory Committee for the UNC Gillings School of Global Public Health.
Q. From which industry sector do you think we will see the most innovation in the next 2 years?
A. Medical imaging: non-invasive diagnosis and staging of disease that can inform real-time intervention.
Q. 2011 is the year of the .....
A. .....patient (as in enduring).
Q. The biggest threat to the US venture capital industry is ...
A. ... the U.S. FDA’s lack of understanding of its role in the cycle of innovation.
Q. What is your favorite book of the last year?
The Other Side of Innovation, Solving the Execution Challengeby Govindarajan & Trimble
Q. Name a venture-backed company you are are not invested in but wish you were.
A. Clarus Therapeutics
Q. Name a practicing VC from another firm who you admire and why?
A. Terry McGuire at Polaris. He’s as smart as they come, a clear thinker, excellent communicator, mentor and respected leader in our industry. I learn something from him every time we interact, whether it’s an email or a board meeting.
More from this author: